KR-31831

KR-31831 is a **synthetic small molecule** with anti-angiogenic and radioprotective activities. It is a **benzopyran derivative** that inhibits angiogenesis by targeting multiple pathways involved in neovascularization, primarily through suppression of **VEGF signaling (downregulation of VEGFR-2/KDR)**, reduction of **FGFR-2** and **basic FGF (bFGF)** expression, and inhibition of **matrix metalloproteinase-2 (MMP-2)** activity, thus preventing proliferation, migration, and tube formation of endothelial cells[1][2][4][7]. In preclinical models, KR-31831 protects hematopoietic cells and radiosensitive tissues against radiation-induced injury, enhances bone marrow and peripheral blood cell recovery, and reduces apoptosis in response to whole-body irradiation, mainly by modulating apoptotic gene expression and the immune response[3][5]. Topical and systemic administration in animal models demonstrated efficacy in reducing corneal and choroidal neovascularization as well as subretinal neovascularization[7][5].

Brand names

HL-217HL217HL 217

Other names

benzopyran derivative KR-31831